Tirzepatide, a drug recently approved by Anvisa, appears as a promising treatment for weight loss and control of type 2 diabetes. This article discusses the potential and safety of Tirzepatide, with a special focus on genomics and its implications for doctors and scientists.
Mechanism of Action of Tirzepatide Tirzepatide is a double agonist of the GLP1 and GIP receptors, different from Ozempic (semaglutide). Its mechanism of action affects the intestinal receptors of these hormones, improving blood glucose levels and reducing appetite, resulting in gradual weight loss.
Genomic Implications in Tirzepatide Treatment The field of genomics has been offering crucial insights into how genetic variations can influence the body’s response to medical treatments, including medications such as Tirzepatide. Genomic studies allow us to better understand the efficacy and potential adverse effects in different populations, providing a more personalized and safe approach to the treatment of obesity and type 2 diabetes (Willard et al., 2020).
Safety and Efficacy of Tirzepatide Clinical studies have shown that Tirzepatide can lead to significant weight loss, with some patients experiencing a reduction of up to 20% in body weight. However, side effects such as nausea, diarrhea and constipation are common. The safety and efficacy of Tirzepatide, especially when compared to other treatments such as insulin and semaglutide, highlight its therapeutic potential (Ludvik et al., 2021).
Tirzepatide represents a new frontier in the treatment of obesity and type 2 diabetes. The integration of genomics in the assessment of its efficacy and safety is crucial for a more precise and personalized medical approach. Although promising, its use must be carefully monitored and always under medical supervision, considering both the benefits and potential risks.
References
- Willard, FS, Douros, JD, Gabe, MB, Showalter, AD, Wainscott, DB, Suter, TM, Capozzi, ME, van der Velden, WJC, Stutsman, C., Cardona, GR, Urva, S., Emmerson, P.J., Holst, J.J., D’Alessio, D., Coghlan, M.P., Rosenkilde, M.M., Campbell, J.E., & Sloop, K.W. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5.
- Ludvik, B., Giorgino, F., Jódar, E., Frias, J.P., Landó, L.F., Brown, K., Bray, R., Rodríguez, A. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomized, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583-598.
CPAH – Heráclito Research and Analysis Center
CPAH, which stands for Heráclito Research and Analysis Center, is an institution dedicated to excellence in research, advanced laboratories, researcher training, publication of scientific journals, professional relocation, method registration, professional training and offering specialized courses.
We stand out as the creators of the innovative GIP project – Genetic Intelligence Project, a pioneer in preparing the first intelligence report through genetic tests, providing an accurate estimate of human IQ.
We invite you to explore more about our activities and achievements at www.cpah.eu. We are committed to driving research, innovation and professional development, contributing to the advancement of science and human intelligence.
